DSE : SILVAPHL
Silva Pharmaceuticals Limited — Key statistics
Pharmaceutical Preparations · Bangladesh
Last price 10.3 BDT (At close: Oct 29, 2026) · Market cap 1.41B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Technical report: trend, RSI, support and resistance, charts
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.41B |
| Enterprise Value | 1.32B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | Dec 2, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 136.50M |
| Shares Outstanding | 136.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 25.05% |
| Owned by Institutions (%) | n/a |
| Float | 64.35M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.27 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 21.19 |
| Quick Ratio | 7.88 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -38.62 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -7.37% |
| Return on Assets (ROA) | -3.98% |
| Return on Invested Capital (ROIC) | -7.28% |
| Return on Capital Employed (ROCE) | -6.77% |
| Weighted Average Cost of Capital (WACC) | 4.35% |
| Revenue Per Employee | 486,181 |
| Profits Per Employee | -227,416 |
| Employee Count | 678 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.57 |
Taxes
| Measure | Value |
|---|
| Income Tax | 12.42M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.02 |
| 52-Week Price Change | +7.29% |
| 50-Day Moving Average | 12.16 |
| 200-Day Moving Average | 12.11 |
| Relative Strength Index (RSI) | 43.86 |
| Average Volume (20 Days) | 331,520 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 329.63M |
| Gross Profit | 85.44M |
| Operating Income | -141.85M |
| Pretax Income | -141.76M |
| Net Income | -154.19M |
| EBITDA | -88.24M |
| EBIT | -141.85M |
| Loss Per Share | -1.13 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 83.80M |
| Total Debt | 2.45M |
| Net Cash | 81.35M |
| Net Cash Per Share | 0.60 |
| Equity (Book Value) | 2.01B |
| Book Value Per Share | 14.76 |
| Working Capital | 712.73M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.36M |
| Capital Expenditures | -3.57M |
| Depreciation & Amortization | 53.60M |
| Net Borrowing | -39.39M |
| Free Cash Flow | -13.93M |
| FCF Per Share | -0.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | 25.92% |
| Operating Margin | -43.03% |
| Pretax Margin | -43.01% |
| Profit Margin | -46.78% |
| EBITDA Margin | -26.77% |
| EBIT Margin | -43.03% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | 0.01 |
| Dividend Yield | 0.10% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 0.10% |
| Earnings Yield | -10.97% |
| FCF Yield | -0.99% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 7, 2019 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 7.95 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |